Recent West African Ebola virus (EBOV) epidemics have led to testing different anti-EBOV vaccines, including a replication-defective adenovirus (RD-Ad) vector (ChAd3-EBOV) and an infectious, replication-competent recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (rVSV-EBOV; also known as rVSV-ZEBOV). While RD-Ads elicit protection, when scaled up to human trials, the level of protection may be much lower than that of vaccines containing viruses that can replicate. Although a replication-competent Ad (RC-Ad) vaccine might generate a level of protection approximating that of rVSV, this infectious vector would also risk causing adenovirus disease. We recently described a "single-cycle" adenovirus (SC-Ad) vector that amplifies antigen genes like RC-Ad, but that avoids the risk of adenovirus infection. Here we have tested an SC-Ad6 vector expressing the glycoprotein (GP) from a 2014 EBOV strain in mice, hamsters, and rhesus macaques. We show that SC-Ad6-EBOV GP induces a high level of serum antibodies in all species and mediates significant protection against pseudo-challenge with rVSV-EBOV expressing luciferase in mice and hamsters. These data suggest that SC-Ad6-EBOV GP may be useful during future EBOV outbreaks.
Ebola virus (EBOV) is a cause of fatal hemorrhagic fever in humans [1, 2] . EBOV was the causative agent of the most recent and largest documented Ebola virus disease (EVD) epidemic, which occurred during 2013-2016 and had a 39.5% case-fatality rate [3, 4] . EBOV displays glycoprotein GP 1,2 , which mediates membrane attachment and fusion on its surface [5, 6] . GP 1, 2 is the primary target for neutralizing antibodies and is thought to be an ideal antigen candidate for EBOV vaccines.
Thirteen vaccine candidates were tested in 2014-2015, during the epidemic [7] . The 2 leading EBOV vaccines were a replication-defective (RD) recombinant chimpanzee adenovirus type 3 vectored vaccine (ChAd3-EBOV; National Institute of Allergy and Infectious Diseases [NIAID] and GlaxoSmithKline) and a replication-competent, recombinant vesicular stomatitis virus vaccine (rVSV-EBOV; also known as rVSV-ZEBOV; NIAID, Public Health Agency of Canada, and Merck) [8] .
rVSV-EBOV generated EBOV binding antibodies regardless of dose in phase 1 trials [9] [10] [11] . While rVSV-EBOV showed efficacy, it is a live replication-competent virus [8, [11] [12] [13] . It infects a cell, replicates its transgene many times, expresses large amounts of antigen, but also produces infectious progeny viruses. Intramuscularly administered rVSV-EBOV was shown to replicate in peripheral tissues and can lead to vaccine-associated arthritis, vasculitis, and dermatitis in both low-and highdose vaccinations [14, 15] .
ChAd3 was effective in nonhuman primate models and also progressed into clinical trials [8, [16] [17] [18] [19] [20] . Phase 1 trials suggested no vaccine-elicited serious adverse events, immunogenicity in high-dose groups, and promising humoral and cell-mediated responses within the range associated with protection in primates [16] [17] [18] 20] .
Although ChAd3 generated EBOV-specific antibody and T-cell responses, its efficacy is limited by the fact that it is a RD vaccine [21] . Unlike rVSV-EBOV, ChAd3-EBOV does not amplify, so it infects 1 cell, delivers 1 viral genome, and expresses only "1X" of the EBOV GP antigen. In primates, EBOV-specific responses generated by ChAd3 were only transient and required boosting with modified vaccinia Ankara to retain durable protection [8, 16, 18, 19] .
Given the lack of antigen replication and amplification by RD-Ads, we developed "single-cycle" Ad (SC-Ad6) vectors that replicate transgenes thousands of times, like replication-competent Ad (RC-Ad), but cannot produce infectious viruses [22] [23] [24] . SC-Ad generates 100-fold more protein than RD-Ads when used at equal doses and equal amounts of antigen as RD-Ad, with 33-100 times fewer viral particles [23, 24] . As an influenza vaccine, SC-Ad6 mediated superior levels of hemagglutination inhibition antibodies and protection after a single intranasal vaccination [22] .
Given the better vaccine effects of SC-Ad and the absence of a safe, Food and Drug Administration-approved, replicating Ad vaccine for EBOV, we tested a SC-Ad6-EBOV GP vaccine expressing a 2014 EBOV GP in mice, hamsters, and rhesus macaques.
MATERIALS AND METHODS

Cell Culture
293 human embryonic kidney cells (Microbix), Vero cells (American Type Culture Collection), and A549 lung carcinoma cells (American Type Culture Collection) were maintained at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS; HyClone) and penicillin/streptomycin at 100 U/mL (Gibco). 293-IIIA-LacI cells were generated by transfection of 293-IIIA cells [24] with the p3'SS plasmid that expresses nuclear targeted LacI repressor [25] . 293-IIIA-LacI cells were cloned after selection in 100 µg/ mL hygromycin B.
SC-Ad6 Expressing EBOV Glycoprotein
A codon-optimized GP complementary DNA encoding EBOVMakona isolate KJ660346 [3] (Genscript) was recombined into SC-Ad6 to generate SC-Ad6-EBOV GP as described elsewhere [22] [23] [24] . Control Ad6 viruses expressing human immunodeficiency virus type 1 (HIV) GP160 (Env) or influenza virus hemagglutinin (HA) were also used. Viruses were rescued, amplified, and purified as previously described [22] [23] [24] . Virus comparisons were performed using virus particles as recommended by Nyberg-Hoffman et al [26] .
rVSV Vectors Pseudotyped With EBOV GP
Recombinant rVSVs expressing the EBOV-Mayinga GP and luciferase (rVSV-EBOV-Luc) were produced as described previously [27] .
Western Blotting
A549 cells were infected with SC-Ad6-EBOV GP or rVSV-EB-OV-Luc at different multiplicities of infection, determined in virus particles/cell or plaque-forming units (PFU)/cell, respectively. Twenty-four hours later, cell lysates were analyzed by Western blotting with primary Syrian hamster antibody against EBOV GP (1:500) and Protein A/G-horseradish peroxidase (1:10 000). SuperSignal West Dura (Thermo Scientific) was added, and blots were imaged on an In Vivo F Station (Kodak). 
Immunizations and Sample Collection
Hamsters were anesthetized with isoflurane and immunized by the indicated routes with the indicated amounts of vaccine. Rhesus macaques were anesthetized with ketamine and immunized by the intranasal or intramuscular route with the indicated amounts of Ad vaccine. At various time points, hamsters were anesthetized, and serum was collected from submandibular veins. In rhesus macaques, plasma samples were collected at each time point before any immunization via peripheral vein.
Pseudo-Challenge With rVSV-EBOV-Luc
Mice (n = 10) were immunized intranasally with 1 × 10 9 viral particles/mL of SC-Ad6-influenza virus HA, SC-Ad6-EBOV GP, or phosphate-buffered saline (PBS). Serum was collected 1 month and 28 days after immunization, before intranasal challenge with 2.5 × 10 5 PFU/mL of rVSV-EBOV-Luc. Serum was also collected 2 and 6 weeks after challenge. Animals were imaged using a Xenogen IVIS instrument on days 1, 3, and 6 after pseudo-challenge, to quantify rVSV-EBOV-Luc infection. In brief, animals were anesthetized with a 100-μL intraperitoneal injection of a solution of ketamine and xylazine. Animals then received a 150-μL intraperitoneal injection and 10 μL per nostril of D-luciferin. Animals were imaged 10 minutes later, and images were analyzed using the Living Image 4.5.2 software. Aged Syrian hamsters were challenged in the same way.
Enzyme-Linked Immunosorbent Assay (ELISA)
Immulon 4 HBX plates (Thermo) were coated with 100 ng/well of recombinant EBOV GP (EBOV rGPdTM; IBT Bioservices) in 1X PBS overnight. Wells were washed and blocked with 200 μL blocking buffer (5% milk and 1X Tris-buffered saline with Tween 20) at room temperature for 2 hours. Wells were washed, and 100 μL of 1:200 dilutions of each sample were added to plates and incubated for 3 hours at room temperature. Wells were washed 4 times, and 100 μL of rabbit anti-hamster anti-immunoglobulin M, immunoglobulin A, and immunoglobulin G-horseradish peroxidase (Brookwood Biomedical, Birmingham, AL) diluted 1:10 000 were added to each well. Plates were incubated for 2 hours at room temperature. Wells were washed 4 times, and 50 μL of 1 step Ultra TMB ELISA (Thermo Fisher Scientific) was added. When color developed, 50 μL of 2 mol/L H 2 SO 4 were added. OD 450 was determined with a Beckman Coulter DTX 880. Assays were conducted similarly for end point-titer ELISAs. Reciprocal titers were statistically defined on the basis of 95% confidence intervals, as determined elsewhere [28] .
rVSV-EBOV-Luc Neutralization Assay
One hundred-microliter serum samples were incubated at 56°C for 0.5 hours. A total of 65 μL of heat-inactivated sera was added to serum-free DMEM to make a 1:10 dilution. A total of 200 μL of each sample was added to the first column of empty 96-well plates (Corning) in triplicate. The remaining wells received 100 μL of serum-free DMEM. A total of 100 μL of diluted plasma was serially transferred from the first column onto the next. rVSV-EBOV-Luc was diluted to 500 PFU/ mL in serum-free DMEM. One hundred microliters (50 PFU) of rVSV-EBOV-Luc was added to each well (except the negative control wells), and samples were incubated for 1 hour at 37°C with rotating at 50 rpm. One hundred microliters of the mixtures was added to 96-well, black-walled, clear-bottomed plates (Corning) containing 80% confluent Vero cells and incubated for 24 hours at 37°C. Luminescence was measured with a Bright-Glo Luciferase Assay System (Promega) on the Beckman Coulter DTX 880 Multimode Detector system.
Statistical Analysis
Prism 7 graphical software was used for all statistical analyses.
RESULTS
Plasmid and SC-Ad6 Expressing EBOV GP
We previously demonstrated that SC-Ad6 vectors expressing green fluorescent protein-luciferase or influenza virus hemagglutinin generate more-robust protein expression and immune responses than RD-Ad6 vectors in vitro and in vivo [22] [23] [24] 29] . We generated a SC-Ad6-EBOV GP vector as previously described [22] [23] [24] 30] (Figure 1 ).
To compare plasmid DNA and Ad gene-based vaccination approaches for EBOV, groups of 5 mice each were immunized intramuscularly. After a single immunization, SC-Ad induced significantly higher EBOV GP-specific antibodies than those generated by the plasmid (P < .01; Supplementary Figure 1 ). Plasmid and Ad vaccines are frequently used in prime-boost immunizations [31] . We tested several combinations of plasmid and Ad prime-boosts. At 14 days and 47 days after boost (68 days after priming), the EBOV GP-specific antibody levels in Ad-primed groups were significantly higher than in plasmid-primed animals (Supplementary Figure 1) .
Single Intranasal Vaccination With Low-Dose SC-Ad6-EBOV GP Induces Persistent Antibodies in Syrian Hamsters
Unlike mice, Syrian hamsters can support the human Ad life cycle and are better models to accurately investigate transgene expression from SC-Ad vaccines [32] . To test SC-Ad in a more permissive animal model, 5 Syrian hamsters were immunized intranasally with PBS or 1 × 10 9 viral particles of SC-Ad6-EBOV GP or SC-Ad6-influenza virus HA (Figure 2 ). This intranasal immunization generated EBOV GP-specific antibodies at titers that peaked 17 weeks (P < .01) after a single vaccination and remained significantly elevated beyond 6 months as compared to controls (at week 31, P < .05 and P < .01 for comparisons of SC-Ad6-EBOV GP recipients to PBS recipients and SC-Ad6-influenza virus HA recipients, respectively).
SC-Ad6-EBOV GP Immunization Generates Robust Immune Responses in
Rhesus Macaques
Groups of 4 female rhesus macaques were immunized intranasally with 2 × 10 10 viral particles of either SC-Ad6-EBOV GP or SC-Ad6 vector expressing HIV GP160. One mucosal immunization generated significant EBOV GP-specific antibodies in plasma within 1 week of vaccination ( Figure 3A Intranasal vaccination with a single-cycle adenovirus 6 (SC-Ad6) vector expressing Ebola virus glycoprotein (SC-Ad6-EBOV GP) elicits robust immune responses. Groups of 5 hamsters received a single immunization of phosphate-buffered saline (PBS) or a low dose of 1 × 10 9 viral particles of SC-Ad6-EBOV GP or SC-Ad6-influenza virus hemagglutinin (HA) (negative control). EBOV GP-binding antibodies were examined at weeks 17 and 31 after immunization. *P < .01, compared with PBS recipients and SC-Ad6-influenza virus HA recipients (week 17); **P < .05, compared with PBS recipients (week 31); and ***P < .01, compared with SC-Ad6-influenza virus HA recipients (week 31) by 1-way analysis of variance.
by switching between the intramuscular route and the mucosal oral route [33] . To test this, macaques were immunized a second time with SC-Ad6, at week 4, using the intramuscular route. No obvious increases in titers of antibodies against the EBOV GP were observed through week 13, although antibody titers in the SC-Ad6-EBOV GP group remained statistically higher than those in the control Ad group ( Figure 3A) . The animals were immunized a third time with SC-Ad6 at week 13, via the intramuscular route. The third immunization increased EBOV GP-specific antibodies significantly in the SC-Ad6-EBOV GP group (P < .0001). The antibody titers remained elevated in plasma after this last boost through 26 weeks after the first immunization (P < .0001). Plasma from the week 15 peak antibody response was serially diluted to calculate end point titers. The 3 immunizations with SC-Ad6-EBOV GP elicited an antibody titer of 1:12 800 ( Figure 3B ). Week 15 peak antibody plasma samples from SC-Ad6-HIV Env recipients and SC-Ad6-EBOV GP recipients were tested for their ability to neutralize rVSV-EBOV-Luc ( Figure 3C ). Plasma from SC-Ad6-EBOV GP had a rVSV-EBOV-Luc neutralizing titer of 1:640 when compared to SC-Ad6-HIV Env samples (P < .01).
SC-Ad6-EBOV GP Immunization Inhibits rVSV-EBOV-Luc Infection after Intranasal Pseudo-Challenge
Groups of 10 CD1 mice were immunized intranasally a single time with 10 9 viral particles of SC-Ad6-EBOV GP, SC-Ad6-influenza virus HA, or PBS. This single vaccination of SC-Ad6-EBOV GP generated strong antibody responses (Figure 4 and Supplementary Figures 2 and 3) , with an end point titer >1:32 000 at 8 weeks and 1:16 000 at 10 and 16 weeks.
At 8 weeks, the animals were pseudo-challenged intranasally with 2.5 × 10 5 PFU of rVSV-EBOV-Luc ( Figure 5 ). rVSVdriven luciferase activity was monitored over time ( Figure 5A ). Under these conditions, SC-Ad mediated significant reductions in rVSV-driven luciferase activity 1 and 3 days after challenge (P < .05; Figure 5B ). Single SC-Ad6-EBOV GP immunization generated antibody levels over 8 weeks that were similar to those generated by the rVSV-EBOV-Luc challenge over 8 weeks in PBS or SC-Ad-influenza virus HA immunized mice (Figure 4 ).
SC-Ad6-EBOV GP Protects Aged Hamsters >1 Year After a Single Vaccination
The PBS control and 3 aged hamsters from Figure 2 Macaques were then boosted intramuscularly at weeks 4 and 13 (black arrows). Plasma was collected at weeks 4, 7, 13, 15, and 26 and evaluated by enzyme-linked immunosorbent assay. *P < .0112 (week 13), *P < .0257 (week 7), **P < .0081, and ****P < .0001. B, Plasma end point titers at peak antibody response. P < .0001, by the t test, at a 1:12 800 dilution for comparison of HIV Env and EBOV GP recipients. C, Week 15 plasma neutralization assay. P < .01, by 1-way analysis of variance, at a 1:640 dilution for comparison of HIV Env and EBOV GP recipients.
EBOV GP Antibodies Figures 2 and 3) . Representative findings of enzyme-linked immunosorbent assays of EBOV GP-binding antibody in sera diluted 1:32 000 are shown. ****P < .0001, by 1-way analysis of variance, for comparison of the SC-Ad6-EBOV GP group to the other groups at each time point.
with rVSV-EBOV-Luc, and luciferase activity was measured ( Figure 6 ). Under these conditions, SC-Ad reduced rVSV-luciferase activity after challenge when compared to controls, although this did not reach significance (P = .055 and .057, by the 1-tailed t test on days 1 and 3, respectively).
DISCUSSION
EBOV vaccines ChAd3-EBOV and rVSV-EBOV both generated promising immune responses in preclinical and human trials [8, 11, 13] . While rVSV-EBOV shows good promise, some vaccinated individuals had side effects and persistent viral loads in peripheral tissues [14, 15] . In contrast, ChAd3-EBOV produced durable responses with no adverse effects, but its immune responses were weaker than those achieved with rVSV-EBOV [8] . This observation was not particularly surprising given that ChAd3-EBOV is a replication-defective vaccine whereas rVSV-EBOV is fully replication competent. Unlike ChAd3-EBOV, rVSV-EBOV amplifies antigen expression via replication and generates infectious progeny virus that can infect an increasing number of cells.
In this study, we explored the usefulness of a replicating, single-cycle Ad (SC-Ad) vector as an alternate EBOV vaccine. Unlike ChAd3-EBOV, SC-Ad vectors retain their E1 gene and their ability to replicate viral DNA up to 10 000 times the initial levels, but they fail to form infectious progeny owing to a deletion of the critical virion cement protein IIIa [22] [23] [24] . Previous work showed that SC-Ads generate significantly higher transgene expression and antibody levels than RD-Ads [22] [23] [24] 29] (data not shown).
We initially compared the ability of naked DNA injection to SC-Ad vaccination for their ability to drive anti-Ebola GP antibodies. Consistent with previous observations, the Ad-vectored vaccine generated markedly stronger immune responses against GP after only 1 immunization. When the animals were boosted with the same or alternate vaccine, antibody titers increased only in the SC-Ad-primed group. For the DNA-primed group, it is unclear why neither vector boosted these responses. Nonetheless, these data suggested that the SC-Ad vaccine was more robust to proceed to testing as a single vaccine.
We showed that single mucosal intranasal immunization of mice or Ad-permissive hamsters with SC-Ad6-EBOV GP generated robust antibodies that persisted for >6 months after 1 mucosal vaccination. We also showed that a single intranasal Ad vaccination with SC-Ad6-EBOV GP generated significant levels of EBOV GP-specific antibodies in rhesus macaques. A single systemic intramuscular boost with the same Ad6 serotype vaccine did not boost these responses, but a second intramuscular dose with the same Ad6 serotype markedly amplified EBOV binding and neutralizing antibodies. Notably, these antibodies persisted for 6 months after priming. This suggests that one may be able to administer 1 SC-Ad serotype by different immunization routes to avoid the expense of generating multiple GMP grade vaccines for prime-boost strategies.
We next tested the vaccine for its ability to resist replication-competent rVSV-EBOV-Luc displaying the EBOV GP that expresses luciferase. This demonstrated that SC-Ad6-EBOV GP mediated significant protection against challenge with this rVSV-EBOV-Luc. SC-Ad and rVSV-EBOV-Luc generated similar kinetics and levels of antibody responses against EBOV GP after 1 exposure to either vector.
Another side benefit of the pseudo-challenge study is that it provides proof of principle for the use of SC-Ad and rVSV-EB-OV-Luc as prime-boost vaccines, a strategy already used by the Russian licensed EBOV vaccines, albeit not with replicating Ad as a platform [34, 35] . Mice primed with SC-Ad6-EBOV GP and then boosted with rVSV-EBOV-Luc generated stronger antibody responses than those only vaccinated with rVSV-EBOV-Luc or with SC-Ad. This suggests a potential coupling of these 2 replicating vaccines to induce possibly stronger and longer-lasting immunity.
Since mice do not support adenovirus replication, these results may underestimate the relative potency of SC-Ad. Likewise, the addition of luciferase to rVSV-EBOV attenuates but does not ablate VSV replication. This leads to an unfair comparison of potency to that observed in vaccine trials with rVSV-EBOV and is not reflective of a true EBOV challenge. We should also emphasize that comparison of the 2 viruses may always be unfair, because they are titered by different methods and choosing an ideal vaccine dose for either will be complicated when comparing in vivo. Ultimately, the best comparisons or combinations of SC-Ad and rVSV will be in human vaccine trials where both viruses can replicate.
These data suggest that SC-Ads may be useful as a vaccine against EBOV in humans. SC-Ad may be useful alone or as a prime-boost strategy perhaps with replication-competent rVSV.
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